ImageneBio Inc

ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImageneBio granted inducement awards of 90,775 RSUs and 32,725 non-qualified stock options to three newly hired non-executive employees on September 30, 2026. The awards were made under the company's 2025 Equity Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), with RSUs vesting over four years and NSOs exercisable at $4.58 per share, the September 30 closing price. This is routine equity compensation boilerplate with no bearing on the company's clinical pipeline, including the ongoing Phase 2b trial of olevaprubart in atopic dermatitis.

•0mo ago

ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York

ImageneBio CEO Kristin Yarema will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on Sept. 14. Management will also hold one-on-one meetings with investors during the event. The company's lead asset, olevaprubart, is currently in a Phase 2b trial for atopic dermatitis.

•1mo ago

ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York

ImageneBio CEO Kristin Yarema will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026. The presentation is scheduled for 12:50 PM EDT and will be webcast live, with an archive available for 90 days on the company's investor relations website. Management will also participate in one-on-one meetings with investors during the conference.

•5mo ago

ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update

ImageneBio reported a first-quarter net loss of $10.6 million, or $0.95 per share, with zero revenue for the period. The company completed a $30 million private placement in April, extending its cash runway into the first quarter of 2028. On the clinical side, the Phase 2b ADAPTIVE trial for lead asset IMG-007 is progressing under an amended protocol, with topline data now expected in the fourth quarter of 2027. Imagene also plans to initiate a Phase 2 study in alopecia areata in 2026, with initial data anticipated in 2028.

•5mo ago